SANTARUS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.:
  • Do you own shares of Santarus, Inc. (NASDAQ GS: SNTS )?
  • Did you purchase any of your shares prior to November 7, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ GS: SNTS) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Salix Pharmaceuticals, Ltd. (“Salix”) (NASDAQ GS: SLXP) in a transaction valued at approximately $2.6 billion.

Click here to learn more: http://www.rigrodskylong.com/investigations/santarus-inc-snts.

Under the terms of the agreement, public shareholders of Santarus will receive $32.00 per share in cash for each share of Santarus they own.

The investigation concerns whether Santarus’s board of directors failed to adequately shop the Company and obtain the best possible value for Santarus’s shareholders before entering into an agreement with Salix.

If you own the common stock of Santarus and purchased your shares before November 7, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/santarus-inc-snts.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

If you liked this article you might like

Investors Expect too Much of Salix

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Santarus (SNTS): Heavy Pre-Market Activity

Salix Pharma to Acquire Santarus

Insider Trading Alert - Santarus And 4 Others Traded By Insiders